Project Oncology®

The ELECTRA trial is seeking to evaluate the combination of elacestrant with abemaciclib in patients with ER+/HER2- metastatic breast cancer regardless of metastatic site and ESR1 status to see if this could be an all-oral treatment option before using fulvestrant-based combinations or chemotherapy-based regimens. And now, the preliminary results are here. Joining Dr. Charles Turck to share what we’ve learned so far from the ELECTRA trial is study investigator Dr. Erika Hamilton.

Based on three randomized-controlled trials, the JAK inhibitor momelotinib has demonstrated clinical activity against anemia, constitutional symptoms, and splenomegaly in patients with myelofibrosis. But what do we know about its long-term safety? That’s what a recent study explored, and now, Dr. Douglas Trembley is here to share the findings from the largest clinical trial safety database for a JAK inhibitor in myelofibrosis. Dr. Trembley is an Assistant Professor at the Icahn School of Medicine at Mount Sinai in New York.

According to the available long-term data, CAR T-cell therapy boosts overall survival and durable remission rates in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). Given this data, it’s important to know how we can best identify appropriate patients for this approach and manage adverse events so they can achieve those long-term benefits. To learn more about the available data and key considerations for using CAR T-cell therapy to treat relapsed/refractory B-ALL, Dr. Gates Colbert speaks with Dr. Ryan Cassaday, Associate Professor in the Division of Hematology-Oncology at the University of Washington School of Medicine in Seattle.

From a relatively poor prognosis to severe toxicity risks, patients with relapsed/refractory acute lymphoblastic leukemia (ALL) and the clinicians caring for them face several treatment challenges. Joining Dr. Charles Turck to discuss those unmet needs—and perhaps even more importantly, how we can address them through expert guidance and emerging therapies—is Dr. Ryan Cassaday, Associate Professor in the Division of Hematology and Oncology at the University of Washington School of Medicine in Seattle.

When it comes to managing patients with high-risk mantle cell lymphoma, several factors impact their candidacy for CAR T-cell therapy, including time to relapse, TP53 mutation status, age, and even social considerations. Joining Dr. Charles Turck to discuss how we can use these factors to identify patients with high-risk mantle cell lymphoma who would most likely benefit from CAR T-cell therapy is medical oncologist Dr. Tara Graff.

The SIMPLIFY-2 trial compared the efficacy of momelotinib to best available therapy, which was primarily continued ruxolitinib, in patients with myelofibrosis and anemia who were previously treated with a JAK inhibitor. According to the findings, momelotinib potentially offers better outcomes and a more comprehensive management strategy by addressing the underlying molecular mechanism of anemia. Learn more about the trial design and results with Dr. Matt Birnholz.

Plasma cell disorders range from multiple myeloma to the monoclonal gammopathy of undetermined significance (MGUS), which is a benign condition that affects anywhere between 3 and 10 percent of the population starting at age 50. However, about 1 percent of people per year who have MGUS will progress to multiple myeloma. Here to talk about common precursor diseases like MGUS and smoldering myeloma and how they can progress to multiple myeloma is Dr. Elizabeth O’Donnell, Director of Early Detection and Prevention at Dana-Farber.

The phase 2 ICARUS-Lung01 study evaluated not only the efficacy and safety of datopotomab deruxtecan (Dato-DXd) in patients with previously treated advanced non-small cell lung cancer (NSCLC), but also potential biomarkers associated with response and/or resistance. Here to discuss the findings with Dr. Charles Turck is Dr. Joshua Reuss, Assistant Professor in the Department of Medicine at Georgetown University Medical Center.

Release date: 8/15/2024
Expiration date: 8/15/2025
Estimated time to complete: 1.0 hour

This activity is not accredited for CME/CE credit.

This episode of Myeloma Matters reviews the latest data on bispecific antibody therapy for relapsed/refractory multiple myeloma (RRMM) discussed at the 2024 American Society of Clinical Oncology (ASCO) and European Hematology Association (EHA) annual meetings, including information about the use of fixed-duration dosing to mitigate adverse events (AEs).

The program includes in-depth discussion and analysis of the latest scientific findings and practice-changing advances in managing RRMM. Expert faculty will place abstract findings into clinical context and discuss strategies for preventing and managing AEs associated with bispecific antibody therapy in RRMM treatment, which include cytokine release syndrome (CRS), neurotoxicity, and infection.

Since multi-cancer early detection (MCED) testing is a new technology, there’s been some discussion in the field about the impact it may have on patients, especially in terms of potential psychological harm like anxiety related to positive test results and false positive test results. Joining Dr. Charles Turck to discuss findings from a recent qualitative survey and the DETECT-A study focusing on how MCED testing may impact patient anxiety are Dr. Christopher Chambers and Mr. Adam Buchanan. Dr. Chambers is a Professor and Director of Clinical Trials at Thomas Jefferson University in Philadelphia, and Mr. Buchanan is an Associate Professor and Chair of the Department of Genomic Health at Geisinger in Danville, Pennsylvania.